Holland Katherine D, Glauser Tracy A
Department of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Neurology. 2007 Aug 7;69(6):596-9. doi: 10.1212/01.wnl.0000267274.69619.f3.
The purpose of this work is to characterize the effectiveness and therapeutic doses of carbamazepine (CBZ) in children with localization-related epilepsy.
Treatment to initial CBZ monotherapy and doses associated with 1-year seizure freedom were examined in 100 consecutive children with partial epilepsy.
Of the 100 patients studied, 55 became seizure-free on CBZ monotherapy, 10 did not tolerate CBZ within the first 3 months of therapy owing to either hypersensitivity or intolerable side effects, and 35 continued to have seizures. In children age <12, over 95% responded at doses below 17.5 mg/kg/day; in children age >12, over 95% responded at below 15 mg/kg/day.
We suggest that other antiepileptic treatments be considered when seizures continue in children taking carbamazepine doses between 15 and 17.5 mg/kg/day even if side effects are absent.
本研究旨在确定卡马西平（CBZ）治疗儿童局灶性癫痫的疗效及治疗剂量。
对100例连续性部分性癫痫患儿进行初始卡马西平单药治疗及与1年无癫痫发作相关剂量的研究。
在100例研究患者中，55例接受卡马西平单药治疗后无癫痫发作，10例在治疗的前3个月因过敏或难以耐受的副作用而不能耐受卡马西平，35例继续有癫痫发作。12岁以下儿童，超过95%在剂量低于17.5mg/kg/天时有效；12岁以上儿童，超过95%在剂量低于15mg/kg/天时有效。
我们建议，即使没有副作用，对于服用卡马西平剂量在15至17.5mg/kg/天之间仍有癫痫发作的儿童，应考虑采用其他抗癫痫治疗方法。
